Akero Therapeutics, Inc.
AKRO
Hisse Senetlerindeki Sıralama
#3724
Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing... Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing cardio-metabolic disorders, with a specific focus on nonalcoholic steatohepatitis (NASH). Its primary objective is the creation of therapeutic agents aimed at re-establishing metabolic equilibrium and enhancing overall well-being. The company's flagship investigational drug is efruxifermin (EFX), a synthetic analog of fibroblast growth factor 21. EFX is designed to shield cells from stress and modulate the systemic metabolism of fats, carbohydrates, and proteins throughout the body. This promising compound is currently undergoing evaluation in a Phase 2a clinical investigation, known as the BALANCED study, for individuals diagnosed with biopsy-confirmed NASH. Originally established as Pippin Pharmaceuticals, Inc., the organization rebranded as Akero Therapeutics, Inc. in May 2018. Founded in 2017, Akero Therapeutics maintains its corporate headquarters in South San Francisco, California.
Hisse Fiyatı
$54.65
Son senkronizasyon: 2025-12-09
Piyasa Değeri
$4.50B
Değişim (1 gün)
0.00%
Değişim (1 yıl)
1.37%
Ülke
US
Ticaret Akero Therapeutics, Inc. (AKRO)
Kategori
Healthcare
Akero Therapeutics, Inc. (AKRO) için kazanç
Sep 2025 itibarıyla kazanç TTM: $-292.82M
Akero Therapeutics, Inc. şirketinin en son finansal raporlarına göre, mevcut kazancı $-292.82M'dir. 2023 yılında şirket $-151.76M kazanç elde etti, bu 2022 yılındaki $-112.03M kazanca göre önceki yıla göre azalma. Bu sayfada gösterilen kazanç, faiz ve vergiler öncesi kazançtır; yani EBIT.
Akero Therapeutics, Inc. için kazanç geçmişi 2017 - 2026
Her yılın sonundaki kazanç
| Yıl | Kazanç | Değiştir |
|---|---|---|
| 2026 (TTM) | $-292.82M | 16.17% |
| 2024 | $-252.06M | 66.09% |
| 2023 | $-151.76M | 35.46% |
| 2022 | $-112.03M | 11.17% |
| 2021 | $-100.78M | 27.23% |
| 2020 | $-79.21M | 81.02% |
| 2019 | $-43.76M | -46.45% |
| 2018 | $-81.71M | 1,690.40% |
| 2017 | $-4.56M | 0.00% |
Benzer şirketler veya rakipler için kazanç
| Şirket | Kazanç | Kazanç Farkı | Ülke |
|---|---|---|---|
| $5.27B | -1,901.41% |
US
|
|
| $-3.09B | 954.23% |
US
|
|
| $-4.02B | 1,271.56% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -766.16% |
NL
|
